Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir

OBJECTIVES: Our aim was to compare the clinical and virological outcomes in Omicron BA.1- and BA.2-infected patients who received sotrovimab with those in patients who received nirmatrelvir for the prevention of severe COVID-19. METHODS: In this multi-centric, prospective ANRS 0003S CoCoPrev cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Blondel, Guillaume, Marcelin, Anne-Geneviève, Soulié, Cathia, Kaisaridi, Sofia, Lusivika-Nzinga, Clovis, Zafilaza, Karen, Dorival, Céline, Nailler, Laura, Boston, Anaïs, Ronchetti, Anne-Marie, Melenotte, Cléa, Cabié, André, Choquet, Christophe, Trinh-Duc, Albert, Lacombe, Karine, Gaube, Géraldine, Coustillères, François, Pourcher, Valérie, Martellosio, Jean-Philippe, Peiffer-Smadja, Nathan, Chauveau, Marie, Housset, Pierre, Piroth, Lionel, Devaux, Mathilde, Pialoux, Gilles, Martin, Aurélie, Dubee, Vincent, Frey, Jérôme, Le Bot, Audrey, Cazanave, Charles, Petua, Philippe, Liblau, Roland, Carrat, Fabrice, Yordanov, Youri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2023
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794519/
https://www.ncbi.nlm.nih.gov/pubmed/36586513
http://dx.doi.org/10.1016/j.cmi.2022.12.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794519/
https://www.ncbi.nlm.nih.gov/pubmed/36586513
http://dx.doi.org/10.1016/j.cmi.2022.12.016

Ejemplares similares